Description
Amigrenin Pharmacodynamics
antimigraine.
Interacts with 5-hydroxytryptamine type 1 receptors located in the smooth muscle of the walls of blood vessels of the brain.
Indications
Treatment of acute migraine attacks (with and without aura).
Contraindications
Hypersensitivity to the drug, CHD, including angina pectoris, hemiplegic, basilar or ophthalmoplegic forms of migraine, peripheral artery occlusive disease, uncontrolled arterial hypertension, stroke or transient cerebrovascular disease in history, liver failure, pregnancy, breast-feeding, children, old age (over 65), simultaneous use with ergotamine and its derivatives.
Caution – epilepsy (including any condition with decreased epileptic threshold), arterial hypertension (controlled), concomitant use of MAO inhibitors and period up to 14 days after their withdrawal.
Dosage and administration
- The tablet should be swallowed in whole with water. In adults single dose – 0.05 g (in some cases – 0.1 g), maximum daily dose – 0.3 g. If migraine symptoms do not disappear and do not decrease after the first dose, the second dose to stop the same attack should not be prescribed. If symptoms reduced or disappeared and then resumed, a second dose may be taken within the next 24 hours. The interval between doses should be at least 2 hours.
